TABLE 3.
Durability of transmission reduction in mice immunized at different ages
| Donor treatment (ages immunized, challenged) | No. of infected BALB/c donors at day 4/total no. of donors (mean titer ± SEM) |
No. of infected CFW contacts/total no. of contacts (mean titer ± SEM) |
% Reduction in transmission vs B/NP-rAd | ||||
|---|---|---|---|---|---|---|---|
| Lung (log10TCID50/mL) | Nasal wash (Log10TCID50/mL) | Total (%) | Lung (log10TCID50/mL) | Nasal wash (Log10TCID50/mL) | Total (%) | ||
| A/NP+M2-rAd i.n. (12 wk, 64 wk) | 0/12 | 7/12 (2.47 ± 0.04) | 7/12 (58.3) | 0/18 | 1/18 (2.69) | 1/18 (5.6) | 92.9 (P < 0.001) |
| B/NP-rAd i.n. (12 wk, 64 wk) | 12/12 (6.01 ± 0.18) | 12/12 (4.36 ± 0.22) | 12/12 (100) | 9/18 (5.21 ± 0.46) | 11/18 (3.60 ± 0.28) | 14/18 (77.8) | |
| A/NP+M2-rAd i.n. (60 wk, 64 wk) |
0/12 | 4/12 (2.88 ± 0.19) | 4/12 (33.3) | 2/18 (5.07 ± 0.38) | 3/18 (3.53 ± 0.51) | 3/18 (16.7) | 76.9 (P < 0.005) |
| B/NP-rAd i.n. (60 wk, 64 wk) | 12/12 (6.20 ± 0.17) | 12/12 (4.49 ± 0.17) | 12/12 (100) | 7/18 (5.25 ± 0.37) | 13/18 (3.88 ± 0.29) | 13/18 (72.2) | |
| A/NP+M2 rAd i.n. (8 wk, 12 wk) | 0/12 | 3/12 (2.45 ± 0.00) | 3/12 (25.0) | 0/18 | 0/18 | 0/18 (0.0) | 100 (P < 0.001) |
| B/NP-rAd i.n. (8 wk, 12 wk) | 12/12 (6.13 ± 0.12) | 12/12 (4.17 ± 0.20) | 12/12 (100) | 2/18 (5.61 ± 0.58) | 11/18 (3.99 ± 0.38) | 12/18 (66.7) | |